Literature DB >> 11182872

Injecting misuse of buprenorphine among French drug users.

Y Obadia1, V Perrin, I Feroni, D Vlahov, J P Moatti.   

Abstract

AIMS: To evaluate the extent to which the introduction (February 1996) of ambulatory prescriptions of buprenorphine for drug maintenance treatment (DMT) has been associated with its intravenous illicit use by French injecting drug users (IDUs).
DESIGN: Cross-sectional survey (September 1997), using self-administered questionnaires, in a sample of IDUs recruited at 32 pharmacies, four needle exchange programmes and three syringe vending machines.
SETTING: Thirty-nine sites where IDUs have access to sterile syringes in the city of Marseille (South-Eastern France). PARTICIPANTS: Sample of IDUs attending community pharmacies, vending machines and needle exchange programs to obtain equipment. MEASUREMENT: To compare characteristics of IDUs who declared that they only injected buprenorphine in the prior 6 months versus the rest of the sample.
FINDINGS: Among the 343 respondents (response rate = 70.7%), 33.8% were polydrug users who occasionally injected buprenorphine in parallel to heroin and/or cocaine, while 23.9% only injected buprenorphine in the previous 6 months. IDUs in this latter group were younger, injected more frequently, and were more frequently on buprenorphine DMT, but they were less likely to be HIV-infected and to declare HIV-related injecting risky behaviours.
CONCLUSIONS: Substantial risk of injecting misuse is associated with large-scale diffusion of buprenorphine DMT. A more stringent regulation for medical dispensation of buprenorphine than the current French general freedom of prescription for all physicians, including general practiioners in ambulatory care, may be necessary in other countries which are considering the diffusion of buprenorphine DMT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182872     DOI: 10.1046/j.1360-0443.2001.96226710.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  38 in total

1.  Policy progress for physician treatment of opiate addiction.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Authors:  Clementina Stimolo; Valentina Del Favero; Giancarlo Zecchinato; Roberto Buson; Davide Cusin; Patrizia Pellachin; Pamela Simonetto
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.

Authors:  Enrico Moratti; Hamid Kashanpour; Tiziana Lombardelli; Maria Maisto
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 4.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  A review of human drug self-administration procedures.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

6.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

7.  Prenatally buprenorphine-exposed children: health to 3 years of age.

Authors:  Kaisa Kivistö; Sarimari Tupola; Satu Kivitie-Kallio
Journal:  Eur J Pediatr       Date:  2015-05-24       Impact factor: 3.183

Review 8.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 9.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

10.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.